BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M, Nakajima Y. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11:2947-2953. [PMID: 15837746 DOI: 10.1158/1078-0432.ccr-04-1469] [Cited by in Crossref: 530] [Cited by in F6Publishing: 319] [Article Influence: 31.2] [Reference Citation Analysis]
Number Citing Articles
1 Gedeon PC, Champion CD, Rhodin KE, Woroniecka K, Kemeny HR, Bramall AN, Bernstock JD, Choi BD, Sampson JH. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Rev Clin Pharmacol 2020;13:1147-58. [PMID: 32862726 DOI: 10.1080/17512433.2020.1817737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014;9:1036-40. [PMID: 24926549 DOI: 10.1097/JTO.0000000000000177] [Cited by in Crossref: 150] [Cited by in F6Publishing: 70] [Article Influence: 21.4] [Reference Citation Analysis]
3 Shao L, Peng Q, Du K, He J, Dong Y, Lin X, Li J, Wu J. Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy. Cancer Manag Res 2017;9:249-58. [PMID: 28721097 DOI: 10.2147/CMAR.S139889] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
4 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017;8:91779-94. [PMID: 29207684 DOI: 10.18632/oncotarget.21586] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 32.8] [Reference Citation Analysis]
5 Zhang XF, Pan K, Weng DS, Chen CL, Wang QJ, Zhao JJ, Pan QZ, Liu Q, Jiang SS, Li YQ, Zhang HX, Xia JC. Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. Oncotarget 2016;7:26670-9. [PMID: 27050369 DOI: 10.18632/oncotarget.8476] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
6 Dong W, Gong M, Shi Z, Xiao J, Zhang J, Peng J. Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies. PLoS One 2016;11:e0152448. [PMID: 27031235 DOI: 10.1371/journal.pone.0152448] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
7 Vandeven N, Nghiem P. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Immunotherapy 2016;8:907-21. [PMID: 27381685 DOI: 10.2217/imt-2016-0009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
8 Xu T, Chai J, Wang K, Jia Q, Liu Y, Wang Y, Xu J, Yu K, Zhao D, Ma J, Fan L, Yan Q, Guo S, Chen G, Chen Q, Xiao H, Liu F, Qi C, Liang R, Li M, Wang Z. Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma. Front Oncol 2021;11:638154. [PMID: 34221962 DOI: 10.3389/fonc.2021.638154] [Reference Citation Analysis]
9 Kwiecień I, Rutkowska E, Polubiec-Kownacka M, Raniszewska A, Rzepecki P, Domagała-Kulawik J. Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry. Transl Lung Cancer Res 2021;10:1679-89. [PMID: 34012784 DOI: 10.21037/tlcr-20-1103] [Reference Citation Analysis]
10 Davern M, Donlon NE, Power R, Hayes C, King R, Dunne MR, Reynolds JV. The tumour immune microenvironment in oesophageal cancer. Br J Cancer 2021;125:479-94. [PMID: 33903730 DOI: 10.1038/s41416-021-01331-y] [Reference Citation Analysis]
11 Qiao YM, Zhang Y. Immunotherapy for esophageal cancer: Current studies and future perspectives. Shijie Huaren Xiaohua Zazhi 2016; 24(36): 4739-4751 [DOI: 10.11569/wcjd.v24.i36.4739] [Reference Citation Analysis]
12 Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023-5039. [PMID: 27574444 DOI: 10.2147/ott.s105862] [Cited by in Crossref: 297] [Cited by in F6Publishing: 192] [Article Influence: 49.5] [Reference Citation Analysis]
13 Zhang Y, Chen X, Zheng H, Zhan Y, Luo J, Yang Y, Ning Y, Wang H, Wang W, Fan S. Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 and predicts a good prognosis in nasopharyngeal carcinoma. J Cancer 2021;12:6118-25. [PMID: 34539884 DOI: 10.7150/jca.60739] [Reference Citation Analysis]
14 Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57. [PMID: 18294387 DOI: 10.1186/1471-2407-8-57] [Cited by in Crossref: 143] [Cited by in F6Publishing: 138] [Article Influence: 10.2] [Reference Citation Analysis]
15 Sudo S, Kajiya H, Okano S, Sasaki M, Katsumata Y, Ohno J, Ikebe T, Hiraki A, Okabe K. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma. Cancer Sci 2020;111:1113-23. [PMID: 32012401 DOI: 10.1111/cas.14336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, Ajarim D, Al-Tweigeri T, Dermime S. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8:190-8. [PMID: 16611412 DOI: 10.1593/neo.05733] [Cited by in Crossref: 379] [Cited by in F6Publishing: 385] [Article Influence: 23.7] [Reference Citation Analysis]
17 Dondero A, Pastorino F, Della Chiesa M, Corrias MV, Morandi F, Pistoia V, Olive D, Bellora F, Locatelli F, Castellano A, Moretta L, Moretta A, Bottino C, Castriconi R. PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology 2016;5:e1064578. [PMID: 26942080 DOI: 10.1080/2162402X.2015.1064578] [Cited by in Crossref: 59] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
18 Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66:794-801. [PMID: 26801886 DOI: 10.1136/gutjnl-2015-310839] [Cited by in Crossref: 206] [Cited by in F6Publishing: 217] [Article Influence: 34.3] [Reference Citation Analysis]
19 Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24:26. [PMID: 28376884 DOI: 10.1186/s12929-017-0329-9] [Cited by in Crossref: 261] [Cited by in F6Publishing: 266] [Article Influence: 52.2] [Reference Citation Analysis]
20 Tanaka K, Miyata H, Sugimura K, Kanemura T, Hamada-Uematsu M, Mizote Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y, Tahara H. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Sci 2016;107:726-33. [PMID: 27015293 DOI: 10.1111/cas.12938] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
21 Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med 2018;16:86. [PMID: 29615076 DOI: 10.1186/s12967-018-1460-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
22 Geng F, Liu J, Guo Y, Li C, Wang H, Wang H, Zhao H, Pan Y. Persistent Exposure to Porphyromonas gingivalis Promotes Proliferative and Invasion Capabilities, and Tumorigenic Properties of Human Immortalized Oral Epithelial Cells. Front Cell Infect Microbiol. 2017;7:57. [PMID: 28286742 DOI: 10.3389/fcimb.2017.00057] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
23 Huang Z, Jin Y, Cai X, Chen L, Shen X, Li B, Chen H, Li Y. Association of the programmed death ligand‐1 combined positive score in tumors and clinicopathological features in esophageal cancer. Thoracic Cancer. [DOI: 10.1111/1759-7714.14285] [Reference Citation Analysis]
24 Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, Kabigting FD, Dasanu CA. Immunotherapy for melanoma: current status and perspectives. J Immunother 2010;33:570-90. [PMID: 20551839 DOI: 10.1097/CJI.0b013e3181e032e8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
25 Vathiotis IA, Gomatou G, Stravopodis DJ, Syrigos N. Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis. Int J Mol Sci 2021;22:5383. [PMID: 34065396 DOI: 10.3390/ijms22105383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, Zhang M, Zheng H, Yang D, Liu L, Mehraein-Ghomi F, Bai X, Chen K, Zhang W, Yang J. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Lett 2020;477:19-30. [PMID: 32120023 DOI: 10.1016/j.canlet.2020.02.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
27 Zhang SS, Tang J, Yu SY, Ma LI, Wang F, Xie SL, Jin L, Yang HY. Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma. Oncol Lett 2015;10:1063-8. [PMID: 26622626 DOI: 10.3892/ol.2015.3274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
28 Chen J, Li H, Pang R, Huang J. Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients. Onco Targets Ther 2017;10:2003-7. [PMID: 28435290 DOI: 10.2147/OTT.S127498] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Inaguma S, Lasota J, Felisiak-Golabek A, Kowalik A, Wang Z, Zieba S, Kalisz J, Ikeda H, Miettinen M. Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression. J Pathol Clin Res 2017;3:268-78. [PMID: 29085667 DOI: 10.1002/cjp2.81] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
30 Cesco-Gaspere M, Morris E, Stauss HJ. Immunomodulation in the treatment of haematological malignancies. Clin Exp Med 2009;9:81-92. [PMID: 19238515 DOI: 10.1007/s10238-009-0037-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
31 Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol. 2017;50:41-48. [PMID: 27922697 DOI: 10.3892/ijo.2016.3785] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
32 Shaikh H, Kamran A, Monga DK. Immunotherapy in gastroesophageal cancers: Current state and future directions. J Oncol Pharm Pract 2021;27:395-404. [PMID: 33050805 DOI: 10.1177/1078155220963538] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Smeltzer JP, Jones JM, Ziesmer SC, Grote DM, Xiu B, Ristow KM, Yang ZZ, Nowakowski GS, Feldman AL, Cerhan JR, Novak AJ, Ansell SM. Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. Clin Cancer Res 2014;20:2862-72. [PMID: 24727328 DOI: 10.1158/1078-0432.CCR-13-2367] [Cited by in Crossref: 63] [Cited by in F6Publishing: 32] [Article Influence: 7.9] [Reference Citation Analysis]
34 Liang X, Sun J, Wu H, Luo Y, Wang L, Lu J, Zhang Z, Guo J, Liang Z, Liu T. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. Diagn Pathol 2018;13:5. [PMID: 29378617 DOI: 10.1186/s13000-017-0678-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
35 Mishra DK, Rocha HJ, Miller R, Kim MP. Immune cells inhibit the tumor metastasis in the 4D cellular lung model by reducing the number of live circulating tumor cells. Sci Rep 2018;8:16569. [PMID: 30410108 DOI: 10.1038/s41598-018-34983-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
36 Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreibelt G, de Boer A, Van Herpen CM, Kaanders JH. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011;121:3100-3108. [PMID: 21765211 DOI: 10.1172/jci43656] [Cited by in Crossref: 177] [Cited by in F6Publishing: 105] [Article Influence: 16.1] [Reference Citation Analysis]
37 Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8:e82870. [PMID: 24349382 DOI: 10.1371/journal.pone.0082870] [Cited by in Crossref: 175] [Cited by in F6Publishing: 182] [Article Influence: 19.4] [Reference Citation Analysis]
38 Zhao S, Sun M, Meng H, Ji H, Liu Y, Zhang M, Li H, Li P, Zhang Y, Zhang Q. TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas. Cancer Manag Res 2019;11:4743-56. [PMID: 31191027 DOI: 10.2147/CMAR.S203156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
39 Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J, Wu C. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol. 2015;20:273-281. [PMID: 24804867 DOI: 10.1007/s10147-014-0701-7] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 8.6] [Reference Citation Analysis]
40 Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. [PMID: 28018338 DOI: 10.3389/fimmu.2016.00550] [Cited by in Crossref: 219] [Cited by in F6Publishing: 226] [Article Influence: 36.5] [Reference Citation Analysis]
41 AiErken N, Shi HJ, Zhou Y, Shao N, Zhang J, Shi Y, Yuan ZY, Lin Y. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. Int J Biol Sci 2017;13:1172-9. [PMID: 29104508 DOI: 10.7150/ijbs.20868] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
42 Kowalski A, Malinowska K, Olszewski J, Zielińska-Bliźniewska H. Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer. Biomolecules 2021;11:970. [PMID: 34356594 DOI: 10.3390/biom11070970] [Reference Citation Analysis]
43 Tsutsumi S, Saeki H, Nakashima Y, Ito S, Oki E, Morita M, Oda Y, Okano S, Maehara Y. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Sci 2017;108:1119-27. [PMID: 28294486 DOI: 10.1111/cas.13237] [Cited by in Crossref: 58] [Cited by in F6Publishing: 66] [Article Influence: 11.6] [Reference Citation Analysis]
44 He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, Lim B, Gong Y. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 2018;149:253-61. [PMID: 29425258 DOI: 10.1093/ajcp/aqx162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
45 Inaguma S, Wang Z, Lasota J, Sarlomo-Rikala M, McCue PA, Ikeda H, Miettinen M. Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors. Am J Surg Pathol 2016;40:1133-42. [PMID: 27158757 DOI: 10.1097/PAS.0000000000000653] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
46 Jomrich G, Silberhumer GR, Marian B, Beer A, Müllauer L. Programmed death-ligand 1 expression in rectal cancer. Eur Surg 2016;48:352-6. [PMID: 28058043 DOI: 10.1007/s10353-016-0447-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
47 Hira-Miyazawa M, Nakamura H, Hirai M, Kobayashi Y, Kitahara H, Bou-Gharios G, Kawashiri S. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. Int J Oncol 2018;52:379-88. [PMID: 29345283 DOI: 10.3892/ijo.2017.4221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
48 Brcic L, Klikovits T, Megyesfalvi Z, Mosleh B, Sinn K, Hritcu R, Laszlo V, Cufer T, Rozman A, Kern I, Mohorcic K, Jakopovic M, Samarzija M, Seiwerth S, Kolek V, Fischer O, Jakubec P, Škarda J, Gieszer B, Hegedus B, Fillinger J, Renyi-Vamos F, Buder A, Bilecz A, Berger W, Grusch M, Hoetzenecker K, Klepetko W, Hoda MA, Filipits M, Dome B. Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study. Transl Lung Cancer Res 2021;10:1594-607. [PMID: 34012777 DOI: 10.21037/tlcr-20-1114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Ring EK, Markert JM, Gillespie GY, Friedman GK. Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. Clin Cancer Res 2017;23:342-50. [PMID: 27836863 DOI: 10.1158/1078-0432.CCR-16-1829] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
50 McCord R, Bolen CR, Koeppen H, Kadel EE 3rd, Oestergaard MZ, Nielsen T, Sehn LH, Venstrom JM. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv 2019;3:531-40. [PMID: 30770362 DOI: 10.1182/bloodadvances.2018020602] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
51 Nowicki TS, Anderson JL, Federman N. Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. Pediatr Res 2016;79:371-7. [PMID: 26595537 DOI: 10.1038/pr.2015.246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
52 Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015-3029. [PMID: 20008522 DOI: 10.1084/jem.20090847] [Cited by in Crossref: 1184] [Cited by in F6Publishing: 1175] [Article Influence: 91.1] [Reference Citation Analysis]
53 Wu YB, Huang YS, Xu YP, Sun YF, Yu DL, Zhang XQ, Long X, Zhu SQ, Zhou JL, Xu JJ. A high level of TM4SF5 is associated with human esophageal cancer progression and poor patient survival. Dig Dis Sci. 2013;58:2623-2633. [PMID: 23633159 DOI: 10.1007/s10620-013-2690-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
54 Puccini A, Battaglin F, Iaia ML, Lenz HJ, Salem ME. Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. J Immunother Cancer 2020;8:e000404. [PMID: 32393474 DOI: 10.1136/jitc-2019-000404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
55 Okadome K, Baba Y, Yasuda-Yoshihara N, Nomoto D, Yagi T, Toihata T, Ogawa K, Sawayama H, Ishimoto T, Iwatsuki M, Iwagami S, Miyamoto Y, Yoshida N, Watanabe M, Komohara Y, Baba H. PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma. Cancer Sci 2021. [PMID: 34773342 DOI: 10.1111/cas.15198] [Reference Citation Analysis]
56 Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Ohshima K. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 2015;126:2193-201. [PMID: 26239088 DOI: 10.1182/blood-2015-02-629600] [Cited by in Crossref: 255] [Cited by in F6Publishing: 261] [Article Influence: 36.4] [Reference Citation Analysis]
57 Wang M, Wang J, Wang R, Jiao S, Wang S, Zhang J, Zhang M. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation. Commun Biol 2019;2:392. [PMID: 31667366 DOI: 10.1038/s42003-019-0642-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
58 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264. [PMID: 22437870 DOI: 10.1038/nrc3239] [Cited by in Crossref: 6827] [Cited by in F6Publishing: 6453] [Article Influence: 682.7] [Reference Citation Analysis]
59 Batman S, Matsuo K, Mhawech-Fauceglia P, Munro E, Weisenberger M, Allen A, Joshi S, Machida H, Matsuzaki S, Bozanovic T, Pejovic T. Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer. Cancers (Basel) 2021;13:1972. [PMID: 33923934 DOI: 10.3390/cancers13081972] [Reference Citation Analysis]
60 Gao C, Xu YJ, Qi L, Bao YF, Zhang L, Zheng L. CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis. Cell Biol Toxicol 2021. [PMID: 34018092 DOI: 10.1007/s10565-021-09613-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Mashima E, Inoue A, Sakuragi Y, Yamaguchi T, Sasaki N, Hara Y, Omoto D, Ohmori S, Haruyama S, Sawada Y, Yoshioka M, Nishio D, Nakamura M. Nivolumab in the treatment of malignant melanoma: review of the literature. Onco Targets Ther 2015;8:2045-51. [PMID: 26273207 DOI: 10.2147/OTT.S62102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
62 Masugi Y, Nishihara R, Yang J, Mima K, da Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak JA, Liao X, Nosho K, Chan AT, Giannakis M, Bass AJ, Hodi FS, Freeman GJ, Rodig S, Fuchs CS, Qian ZR, Ogino S. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 2017;66:1463-73. [PMID: 27196573 DOI: 10.1136/gutjnl-2016-311421] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 15.7] [Reference Citation Analysis]
63 van der Wilk BJ, Eyck BM, Lagarde SM, van der Gaast A, Nuyttens JJME, Wijnhoven BPL, van Lanschot JJB. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis 2019;11:S621-31. [PMID: 31080638 DOI: 10.21037/jtd.2018.11.143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
64 Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol. 2015;6:561-569. [PMID: 26487950 DOI: 10.3978/j.issn.2078-6891.2015.037] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
65 Long J, Lin J, Wang A, Wu L, Zheng Y, Yang X, Wan X, Xu H, Chen S, Zhao H. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol. 2017;10:146. [PMID: 28774337 DOI: 10.1186/s13045-017-0511-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
66 Chen K, Zhu Z, Zhang N, Cheng G, Zhang F, Jin J, Wu J, Ying L, Mao W, Su D. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma. Med Sci Monit 2017;23:4619-32. [PMID: 28949934 DOI: 10.12659/msm.904154] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
67 Arpin D, Charpentier MC, Bernardi M, Monnet I, Boni A, Watkin E, Goubin-Versini I, Lamy R, Gérinière L, Geier M, Forest F, Gervais R, Madrosyk A, Guisier F, Serrand C, Locher C, Decroisette C, Fournel P, Auliac JB, Jeanfaivre T, Letreut J, Doubre H, Francois G, Piton N, Chouaïd C, Damotte D. PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study. Ther Adv Med Oncol 2020;12:1758835920937972. [PMID: 32684990 DOI: 10.1177/1758835920937972] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
68 Chang YL, Yang CY, Huang YL, Wu CT, Yang PC. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget 2017;8:18021-30. [PMID: 28152514 DOI: 10.18632/oncotarget.14935] [Cited by in Crossref: 24] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
69 Xie Y, Shi X, Chen Y, Wu B, Gong X, Lu W, Lin W. The intra-class heterogeneity of immunophenotyping and immune landscape in oesophageal cancer and clinical implications. Ann Med 2021;53:626-38. [PMID: 33860722 DOI: 10.1080/07853890.2021.1912385] [Reference Citation Analysis]
70 Mkrtichyan M, Najjar YG, Raulfs EC, Liu L, Langerman S, Guittard G, Ozbun L, Khleif SN. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J Immunol 2012;189:2338-47. [PMID: 22837483 DOI: 10.4049/jimmunol.1103085] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
71 Safaei HR, Rostamzadeh A, Rahmani O, Mohammadi M, Ghaderi O, Yahaghi H, Ahmadi K. Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma. Tumour Biol 2016;37:7583-7. [PMID: 26687644 DOI: 10.1007/s13277-015-4652-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
72 Spain L, Younger E, Hatipoglu E, Larkin J. Pembrolizumab in the management of metastatic melanoma. Melanoma Manag 2015;2:315-25. [PMID: 30190860 DOI: 10.2217/mmt.15.33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
73 Accordino G, Lettieri S, Bortolotto C, Benvenuti S, Gallotti A, Gattoni E, Agustoni F, Pozzi E, Rinaldi P, Primiceri C, Morbini P, Lancia A, Stella GM. From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancers-A Multidisciplinary Perspective. Cancers (Basel) 2020;12:E2105. [PMID: 32751137 DOI: 10.3390/cancers12082105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, Levine BL, June CH, Medin JA, Fowler DH. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 2011;3:111ra120. [PMID: 22133721 DOI: 10.1126/scitranslmed.3003130] [Cited by in Crossref: 236] [Cited by in F6Publishing: 230] [Article Influence: 23.6] [Reference Citation Analysis]
75 Tao J, Dai J, Hou S. Association between B7-H1 and cervical cancer: B7-H1 impairs the immune response in human cervical cancer cells. Exp Ther Med 2017;14:4125-33. [PMID: 29104629 DOI: 10.3892/etm.2017.5100] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Kollmann D, Schweiger T, Schwarz S, Ignatova D, Chang YT, Lewik G, Schoppmann SF, Hoetzenecker W, Klepetko W, Guenova E, Hoetzenecker K. PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer. Oncoimmunology 2017;6:e1331194. [PMID: 28932634 DOI: 10.1080/2162402X.2017.1331194] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
77 Hansel C, Erschfeld S, Baues M, Lammers T, Weiskirchen R, Trautwein C, Kroy DC, Drescher HK. The Inhibitory T Cell Receptors PD1 and 2B4 Are Differentially Regulated on CD4 and CD8 T Cells in a Mouse Model of Non-alcoholic Steatohepatitis. Front Pharmacol 2019;10:244. [PMID: 30949049 DOI: 10.3389/fphar.2019.00244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Taniura T, Iida Y, Kotani H, Ishitobi K, Tajima Y, Harada M. Immunogenic chemotherapy in two mouse colon cancer models. Cancer Sci 2020;111:3527-39. [PMID: 32816355 DOI: 10.1111/cas.14624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Huang KC, Chiang SF, Chen TW, Chen WT, Yang PC, Ke TW, Chao KSC. Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy. Sci Rep 2020;10:22330. [PMID: 33339860 DOI: 10.1038/s41598-020-79419-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
80 Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol 2017;13:919-34. [PMID: 28067073 DOI: 10.2217/fon-2016-0422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Parise IZS, Parise GA, Noronha L, Surakhy M, Woiski TD, Silva DB, Costa TEB, Del-Valle MHCP, Komechen H, Rosati R, Ribeiro MG, Nascimento ML, Souza JA, Andrade DP, Paraizo MM, Galvão MMR, Barbosa JRS, Barbosa ML, Custódio GC, Figueiredo MMO, Fabro ALMR, Bond G, Volante M, Lalli E, Figueiredo BC. The Prognostic Role of CD8+ T Lymphocytes in Childhood Adrenocortical Carcinomas Compared to Ki-67, PD-1, PD-L1, and the Weiss Score. Cancers (Basel) 2019;11:E1730. [PMID: 31694270 DOI: 10.3390/cancers11111730] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
82 Shimizu A, Kaira K, Okubo Y, Utsumi D, Yasuda M, Asao T, Nishiyama M, Takahashi K, Ishikawa O. Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma. J Glob Oncol 2017;3:360-9. [PMID: 28831444 DOI: 10.1200/JGO.2016.005843] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
83 Xiang X, Yu PC, Long D, Liao XL, Zhang S, You XM, Zhong JH, Li LQ. Prognostic value of PD -L1 expression in patients with primary solid tumors. Oncotarget 2018;9:5058-72. [PMID: 29435162 DOI: 10.18632/oncotarget.23580] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
84 Myint ZW, Goel G. Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol. 2017;10:86. [PMID: 28434400 DOI: 10.1186/s13045-017-0454-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
85 Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012;1:1223-1225. [PMID: 23243584 DOI: 10.4161/onci.21335] [Cited by in Crossref: 218] [Cited by in F6Publishing: 217] [Article Influence: 218.0] [Reference Citation Analysis]
86 Cho J, Kang MS, Kim KM. Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response. J Gastric Cancer. 2016;16:1-7. [PMID: 27104020 DOI: 10.5230/jgc.2016.16.1.1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
87 Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A 2015;112:E966-72. [PMID: 25730880 DOI: 10.1073/pnas.1500712112] [Cited by in Crossref: 261] [Cited by in F6Publishing: 243] [Article Influence: 37.3] [Reference Citation Analysis]
88 Chen MF, Chen PT, Chen WC, Lu MS, Lin PY, Lee KD. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression. Oncotarget 2016;7:7913-24. [PMID: 26761210 DOI: 10.18632/oncotarget.6861] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 11.8] [Reference Citation Analysis]
89 Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H, Li H, Luo X, Ye T, Sun Y, Chen H. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014;7:567-73. [PMID: 24748806 DOI: 10.2147/OTT.S59959] [Cited by in Crossref: 129] [Cited by in F6Publishing: 107] [Article Influence: 16.1] [Reference Citation Analysis]
90 Jia L, Zhang Q, Zhang R. PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biol Med. 2018;15:116-123. [PMID: 29951336 DOI: 10.20892/j.issn.2095-3941.2017.0086] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
91 Gao Y, Li S, Xu D, Chen S, Cai Y, Jiang W, Zhang X, Sun J, Wang K, Chang B. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Chin J Cancer. 2017;36:61. [PMID: 28754154 DOI: 10.1186/s40880-017-0226-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
92 Di Federico A, De Giglio A, Parisi C, Gelsomino F, Boni L, Ardizzoni A. Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis. JTO Clin Res Rep 2021;2:100214. [PMID: 34590054 DOI: 10.1016/j.jtocrr.2021.100214] [Reference Citation Analysis]
93 Marinelli O, Annibali D, Aguzzi C, Tuyaerts S, Amant F, Morelli MB, Santoni G, Amantini C, Maggi F, Nabissi M. The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies. Front Oncol 2019;9:1073. [PMID: 31681606 DOI: 10.3389/fonc.2019.01073] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
94 Chen K, Cheng G, Zhang F, Zhang N, Li D, Jin J, Wu J, Ying L, Mao W, Su D. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget 2016;7:30772-80. [PMID: 27120796 DOI: 10.18632/oncotarget.8956] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 12.6] [Reference Citation Analysis]
95 Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014;2:361-70. [PMID: 24764583 DOI: 10.1158/2326-6066.CIR-13-0127] [Cited by in Crossref: 543] [Cited by in F6Publishing: 335] [Article Influence: 67.9] [Reference Citation Analysis]
96 Thompson RH, Kwon ED, Allison JP. Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy 2009;1:129-39. [PMID: 20445772 DOI: 10.2217/1750743X.1.1.129] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
97 Akutsu Y, Murakami K, Kano M, Toyozumi T, Matsumoto Y, Takahashi M, Otsuka R, Sekino N, Yokoyama M, Shiraishi T, Matsubara H. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. Esophagus 2018;15:103-8. [PMID: 29892935 DOI: 10.1007/s10388-018-0604-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
98 Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014;2:643-54. [PMID: 24903021 DOI: 10.1158/2326-6066.CIR-13-0215] [Cited by in Crossref: 167] [Cited by in F6Publishing: 101] [Article Influence: 20.9] [Reference Citation Analysis]
99 Zhang H, Deng M, Lin P, Liu J, Liu C, Strohl WR, Wang S, Ho M. Frontiers and Opportunities: Highlights of the 2nd Annual Conference of the Chinese Antibody Society. Antib Ther 2018;1:65-74. [PMID: 30406214 DOI: 10.1093/abt/tby009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
100 Zhao L, Li C, Liu F, Zhao Y, Liu J, Hua Y, Liu J, Huang J, Ge C. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther 2017;10:2115-26. [PMID: 28442920 DOI: 10.2147/OTT.S130481] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
101 Tao H, Qian P, Wang F, Yu H, Guo Y. Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model. Oncol Res. 2017;25:1579-1587. [PMID: 28337964 DOI: 10.3727/096504017x14900505020895] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
102 Gutierrez-Sainz L, Cruz P, Martinez-Recio S, Higuera O, Esteban-Rodriguez MI, Arias-Lotto F, Gonzalez RA, De Castro-Carpeño J. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression. Clin Transl Oncol 2021;23:2030-5. [PMID: 33837910 DOI: 10.1007/s12094-021-02605-w] [Reference Citation Analysis]
103 Moy JD, Moskovitz JM, Ferris RL. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer 2017;76:152-66. [PMID: 28324750 DOI: 10.1016/j.ejca.2016.12.035] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 10.0] [Reference Citation Analysis]
104 Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One 2015;10:e0121071. [PMID: 25774992 DOI: 10.1371/journal.pone.0121071] [Cited by in Crossref: 135] [Cited by in F6Publishing: 116] [Article Influence: 19.3] [Reference Citation Analysis]
105 Wang BJ, Bao JJ, Wang JZ, Wang Y, Jiang M, Xing MY, Zhang WG, Qi JY, Roggendorf M, Lu MJ, Yang DL. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol 2011; 17(28): 3322-3329 [PMID: 21876620 DOI: 10.3748/wjg.v17.i28.3322] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 85] [Article Influence: 7.6] [Reference Citation Analysis]
106 Yokoyama S, Miyoshi H. Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma. J Thorac Dis 2020;12:7553-60. [PMID: 33447446 DOI: 10.21037/jtd-19-3703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Stasikowska-Kanicka O, Wągrowska-Danilewicz M, Danilewicz M. Immunohistochemical Analysis of Foxp3+, CD4+, CD8+ Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma. Pathol Oncol Res 2018;24:497-505. [PMID: 28669079 DOI: 10.1007/s12253-017-0270-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
108 Humphries MP, Craig SG, Kacprzyk R, Fisher NC, Bingham V, McQuaid S, Murray GI, McManus D, Turkington RC, James J, Salto-Tellez M. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. BMC Cancer 2020;20:500. [PMID: 32487090 DOI: 10.1186/s12885-020-06987-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
109 Obeid JM, Erdag G, Smolkin ME, Deacon DH, Patterson JW, Chen L, Bullock TN, Slingluff CL. PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunology 2016;5:e1235107. [PMID: 27999753 DOI: 10.1080/2162402X.2016.1235107] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
110 Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21:24-33. [PMID: 25440090 DOI: 10.1016/j.molmed.2014.10.009] [Cited by in Crossref: 317] [Cited by in F6Publishing: 327] [Article Influence: 39.6] [Reference Citation Analysis]
111 Ma Y, Zhang P, An G, Zhang X, Zhang L, Si J, Zhang J, Yang Y. Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients. Med Sci Monit 2016;22:4017-25. [PMID: 27784882 DOI: 10.12659/msm.900661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
112 Bae SU, Jeong WK, Baek SK, Kim NK, Hwang I. Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer. Oncol Lett 2018;16:5214-22. [PMID: 30250590 DOI: 10.3892/ol.2018.9264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
113 Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC Jr, Haugen BR, French JD. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab 2016;101:2863-73. [PMID: 27045886 DOI: 10.1210/jc.2015-4227] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 13.3] [Reference Citation Analysis]
114 Chiavenna SM, Jaworski JP, Vendrell A. State of the art in anti-cancer mAbs. J Biomed Sci 2017;24:15. [PMID: 28219375 DOI: 10.1186/s12929-016-0311-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
115 Jiang D, Song Q, Wang H, Huang J, Wang H, Hou J, Li X, Xu Y, Sujie A, Zeng H, Tan L, Hou Y. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Oncotarget 2017;8:8315-29. [PMID: 28039448 DOI: 10.18632/oncotarget.14174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
116 Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R, Walfish PG. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget 2016;7:32318-28. [PMID: 27086918 DOI: 10.18632/oncotarget.8698] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 16.2] [Reference Citation Analysis]
117 Dong L, Lv H, Li W, Song Z, Li L, Zhou S, Qiu L, Qian Z, Liu X, Feng L, Meng B, Fu K, Wang X, Pan-Hammarström Q, Wang P, Wang X, Zhang H. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Oncotarget 2016;7:33350-62. [PMID: 27147575 DOI: 10.18632/oncotarget.9061] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
118 Huang ZL, Liu S, Wang GN, Zheng SH, Ding SR, Tao YL, Chen C, Liu SR, Yang X, Chang H, Wang XH, Xia YF. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Cancer Cell Int 2019;19:141. [PMID: 31139018 DOI: 10.1186/s12935-019-0863-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
119 Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget 2017;8:97671-82. [PMID: 29228642 DOI: 10.18632/oncotarget.18311] [Cited by in Crossref: 124] [Cited by in F6Publishing: 129] [Article Influence: 24.8] [Reference Citation Analysis]
120 Park R, Da Silva LL, Saeed A. Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond. Cancers (Basel) 2021;13:1715. [PMID: 33916348 DOI: 10.3390/cancers13071715] [Reference Citation Analysis]
121 Zhu Q, Cai MY, Chen CL, Hu H, Lin HX, Li M, Weng DS, Zhao JJ, Guo L, Xia JC. Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. Oncoimmunology 2017;6:e1312240. [PMID: 28638740 DOI: 10.1080/2162402X.2017.1312240] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 8.2] [Reference Citation Analysis]
122 Tian H, Shi G, Wang Q, Li Y, Yang Q, Li C, Yang G, Wu M, Xie Q, Zhang S, Yang Y, Xiang R, Yu D, Wei Y, Deng H. A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. Signal Transduct Target Ther 2016;1:16025. [PMID: 29263903 DOI: 10.1038/sigtrans.2016.25] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
123 Martin-Orozco N, Dong C. Inhibitory costimulation and anti-tumor immunity. Semin Cancer Biol 2007;17:288-98. [PMID: 17683946 DOI: 10.1016/j.semcancer.2007.06.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
124 Lin EW, Karakasheva TA, Hicks PD, Bass AJ, Rustgi AK. The tumor microenvironment in esophageal cancer. Oncogene 2016;35:5337-49. [PMID: 26923327 DOI: 10.1038/onc.2016.34] [Cited by in Crossref: 119] [Cited by in F6Publishing: 128] [Article Influence: 19.8] [Reference Citation Analysis]
125 Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104:3360-3365. [PMID: 17360651 DOI: 10.1073/pnas.0611533104] [Cited by in Crossref: 946] [Cited by in F6Publishing: 908] [Article Influence: 63.1] [Reference Citation Analysis]
126 Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, Anders RA, Topalian SL, Taube JM. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013;1:54-63. [PMID: 24416729 DOI: 10.1158/2326-6066.CIR-13-0034] [Cited by in Crossref: 250] [Cited by in F6Publishing: 140] [Article Influence: 35.7] [Reference Citation Analysis]
127 Piersma SJ. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron 2011;4:361-75. [PMID: 21626415 DOI: 10.1007/s12307-011-0066-7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 5.7] [Reference Citation Analysis]
128 Takeuchi M, Miyoshi H, Asano N, Yoshida N, Yamada K, Yanagida E, Moritsubo M, Nakata M, Umeno T, Suzuki T, Komaki S, Muta H, Furuta T, Seto M, Ohshima K. Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma. Haematologica 2019;104:1626-32. [PMID: 30630986 DOI: 10.3324/haematol.2018.205567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
129 Mahmoudian RA, Mozhgani S, Abbaszadegan MR, Mokhlessi L, Montazer M, Gholamin M. Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC. J Mol Histol 2021;52:597-609. [PMID: 33884540 DOI: 10.1007/s10735-021-09971-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Lam ST, Huang H, Fang X, Wang Z, Hong H, Ren Q, Tian Y, Lin S, Lin T. A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy. Cancer Manag Res 2020;12:1981-90. [PMID: 32231439 DOI: 10.2147/CMAR.S244176] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Ishii H, Azuma K, Kawahara A, Matsuo N, Tokito T, Kinoshita T, Yamada K, Sasada T, Akiba J, Hoshino T. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget 2017;8:61618-25. [PMID: 28977890 DOI: 10.18632/oncotarget.18651] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
132 Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Turrini O, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F. Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget 2016;7:71198-210. [PMID: 27589570 DOI: 10.18632/oncotarget.11685] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 11.5] [Reference Citation Analysis]
133 Wang L, Han H, Wang Z, Shi L, Yang M, Qin Y. Targeting the Microenvironment in Esophageal Cancer. Front Cell Dev Biol 2021;9:684966. [PMID: 34513829 DOI: 10.3389/fcell.2021.684966] [Reference Citation Analysis]
134 Borcoman E, Le Tourneau C. Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. Ther Adv Med Oncol 2017;9:431-9. [PMID: 28607581 DOI: 10.1177/1758834017708742] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 8.6] [Reference Citation Analysis]
135 Yamamoto N, Nokihara H, Yamada Y, Shibata T, Tamura Y, Seki Y, Honda K, Tanabe Y, Wakui H, Tamura T. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest New Drugs 2017;35:207-16. [PMID: 27928714 DOI: 10.1007/s10637-016-0411-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
136 Kim R, Keam B, Kwon D, Ock CY, Kim M, Kim TM, Kim HJ, Jeon YK, Park IK, Kang CH, Kim DW, Kim YT, Heo DS. Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. World J Gastroenterol 2016; 22(37): 8389-8397 [PMID: 27729745 DOI: 10.3748/wjg.v22.i37.8389] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
137 Fakih M, Ouyang C, Wang C, Tu TY, Gozo MC, Cho M, Sy M, Longmate JA, Lee PP. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. J Clin Invest 2019;129:4464-76. [PMID: 31524634 DOI: 10.1172/JCI127046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
138 Ammannagari N, Atasoy A. Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. J Gastrointest Oncol 2018;9:196-207. [PMID: 29564185 DOI: 10.21037/jgo.2017.06.12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
139 Seliger B. Basis of PD1/PD-L1 Therapies. J Clin Med 2019;8:E2168. [PMID: 31817953 DOI: 10.3390/jcm8122168] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
140 Haghshenas MR, Naeimi S, Talei A, Ghaderi A, Erfani N. Program death 1 (PD1) haplotyping in patients with breast carcinoma. Mol Biol Rep 2011;38:4205-10. [PMID: 21113674 DOI: 10.1007/s11033-010-0542-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
141 Chang H, Hong JH, Lee JK, Cho HW, Ouh YT, Min KJ, So KA. Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization. J Gynecol Oncol 2018;29:e27. [PMID: 29400020 DOI: 10.3802/jgo.2018.29.e27] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
142 Kim JH, Kim K, Kim M, Kim YM, Suh JH, Cha HJ, Choi HJ. Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer. J Pathol Transl Med 2020;54:154-64. [PMID: 32028754 DOI: 10.4132/jptm.2019.11.13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
143 Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, Weber WP, Soysal SD. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014;146:15-24. [PMID: 24842267 DOI: 10.1007/s10549-014-2988-5] [Cited by in Crossref: 302] [Cited by in F6Publishing: 320] [Article Influence: 37.8] [Reference Citation Analysis]
144 Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2014;2:690-8. [PMID: 24866169 DOI: 10.1158/2326-6066.CIR-13-0224] [Cited by in Crossref: 114] [Cited by in F6Publishing: 80] [Article Influence: 14.3] [Reference Citation Analysis]
145 Liu J, Wang L, Gao W, Li L, Cui X, Yang H, Lin W, Dang Q, Zhang N, Sun Y. Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10. Diagn Pathol 2014;9:85. [PMID: 24762057 DOI: 10.1186/1746-1596-9-85] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
146 Qiao Y, Liu C, Zhang X, Zhou Q, Li Y, Xu Y, Gao Z, Xu Y, Kong L, Yang A, Mei M, Ren Y, Wang X, Zhou X. PD-L2 based immune signature confers poor prognosis in HNSCC. Oncoimmunology 2021;10:1947569. [PMID: 34377590 DOI: 10.1080/2162402X.2021.1947569] [Reference Citation Analysis]
147 Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101 [PMID: 26306141 DOI: 10.4251/wjgo.v7.i8.95] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
148 Lin EM, Gong J, Klempner SJ, Chao J. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. World J Gastroenterol 2018; 24(25): 2686-2697 [PMID: 29991874 DOI: 10.3748/wjg.v24.i25.2686] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
149 Jiang Y, Lo AWI, Wong A, Chen W, Wang Y, Lin L, Xu J. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Oncotarget 2017;8:30175-89. [PMID: 28404915 DOI: 10.18632/oncotarget.15621] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 12.5] [Reference Citation Analysis]
150 Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.J Leukoc Biol. 2013;94:25-39. [PMID: 23625198 DOI: 10.1189/jlb.1212621] [Cited by in Crossref: 219] [Cited by in F6Publishing: 204] [Article Influence: 24.3] [Reference Citation Analysis]
151 Zhao YJ, Sun WP, Peng JH, Deng YX, Fang YJ, Huang J, Zhang HZ, Wan DS, Lin JZ, Pan ZZ. Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. Cancer Manag Res 2018;10:1-11. [PMID: 29296096 DOI: 10.2147/CMAR.S153965] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
152 Roufas C, Chasiotis D, Makris A, Efstathiades C, Dimopoulos C, Zaravinos A. The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. Front Oncol 2018;8:27. [PMID: 29515971 DOI: 10.3389/fonc.2018.00027] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
153 Billon E, Finetti P, Bertucci A, Niccoli P, Birnbaum D, Mamessier E, Bertucci F. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. Oncoimmunology 2019;8:e1655362. [PMID: 31646101 DOI: 10.1080/2162402X.2019.1655362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
154 Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F, Shen S. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget. 2016;7:45370-45384. [PMID: 27248318 DOI: 10.18632/oncotarget.9659] [Cited by in Crossref: 107] [Cited by in F6Publishing: 118] [Article Influence: 26.8] [Reference Citation Analysis]
155 Gyorki DE, Callahan M, Wolchok JD, Ariyan CE. The delicate balance of melanoma immunotherapy. Clin Transl Immunology 2013;2:e5. [PMID: 25505953 DOI: 10.1038/cti.2013.5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
156 Zhu Y, Li M, Mu D, Kong L, Zhang J, Zhao F, Li Z, Liu X, Bo C, Yu J. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Oncotarget 2016;7:71455-65. [PMID: 27683115 DOI: 10.18632/oncotarget.12213] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
157 Jin Z, Yoon HH. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. J Gastrointest Oncol 2016;7:771-88. [PMID: 27747091 DOI: 10.21037/jgo.2016.08.06] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
158 Lee H, Kim JH, Yang SY, Kong J, Oh M, Jeong DH, Chung JI, Bae KB, Shin JY, Hong KH. Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients. J Cancer Res Clin Oncol. 2010;136:1445-1452. [PMID: 20140740 DOI: 10.1007/s00432-010-0800-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
159 Tsukamoto M, Imai K, Ishimoto T, Komohara Y, Yamashita YI, Nakagawa S, Umezaki N, Yamao T, Kitano Y, Miyata T, Arima K, Okabe H, Baba Y, Chikamoto A, Ishiko T, Hirota M, Baba H. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Cancer Sci 2019;110:310-20. [PMID: 30426611 DOI: 10.1111/cas.13874] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
160 Singh V, Khurana A, Allawadhi P, Banothu AK, Bharani KK, Weiskirchen R. Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. Front Pharmacol 2021;12:790963. [PMID: 35002724 DOI: 10.3389/fphar.2021.790963] [Reference Citation Analysis]
161 Oestreich KJ, Yoon H, Ahmed R, Boss JM. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 2008;181:4832-9. [PMID: 18802087 DOI: 10.4049/jimmunol.181.7.4832] [Cited by in Crossref: 217] [Cited by in F6Publishing: 209] [Article Influence: 15.5] [Reference Citation Analysis]
162 Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4. [PMID: 26936508 DOI: 10.1126/scitranslmed.aad7118] [Cited by in Crossref: 1022] [Cited by in F6Publishing: 1034] [Article Influence: 170.3] [Reference Citation Analysis]
163 Kojima M, Murata S, Mekata E, Takebayashi K, Jaffee EM, Tani T. Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine. J Immunother 2014;37:147-54. [PMID: 24598447 DOI: 10.1097/CJI.0000000000000025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
164 Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. J Cancer 2021;12:2735-46. [PMID: 33854633 DOI: 10.7150/jca.57334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
165 Fei Z, Deng Z, Zhou L, Li K, Xia X, Xie R. PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway. Oncol Res 2019;27:801-7. [PMID: 30982497 DOI: 10.3727/096504018X15446984186056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
166 Karami S, Sattarifard H, Kiumarsi M, Sarabandi S, Taheri M, Hashemi M, Bahari G, Ghavami S. Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women. Asian Pac J Cancer Prev 2020;21:3115-23. [PMID: 33112575 DOI: 10.31557/APJCP.2020.21.10.3115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
167 Lee VH, Lo AW, Leung CY, Shek WH, Kwong DL, Lam KO, Tong CC, Sze CK, Leung TW. Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma. PLoS One 2016;11:e0157969. [PMID: 27341634 DOI: 10.1371/journal.pone.0157969] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
168 Luan S, Zeng X, Zhang C, Qiu J, Yang Y, Mao C, Xiao X, Zhou J, Zhang Y, Yuan Y. Advances in Drug Resistance of Esophageal Cancer: From the Perspective of Tumor Microenvironment. Front Cell Dev Biol 2021;9:664816. [PMID: 33816512 DOI: 10.3389/fcell.2021.664816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Wu X, Zhang H, Xing Q, Cui J, Li J, Li Y, Tan Y, Wang S. PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer. 2014;111:1391-1399. [PMID: 25093496 DOI: 10.1038/bjc.2014.416] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 7.9] [Reference Citation Analysis]
170 Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19:1021-34. [PMID: 23460533 DOI: 10.1158/1078-0432.CCR-12-2063] [Cited by in Crossref: 327] [Cited by in F6Publishing: 213] [Article Influence: 36.3] [Reference Citation Analysis]
171 Wirta EV, Szeto S, Hänninen U, Ahtiainen M, Böhm J, Mecklin JP, Aaltonen LA, Seppälä TT. Prognostic Value of Immune Environment Analysis in Small Bowel Adenocarcinomas with Verified Mutational Landscape and Predisposing Conditions. Cancers (Basel) 2020;12:E2018. [PMID: 32718028 DOI: 10.3390/cancers12082018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
172 Cho J, Lee J, Bang H, Kim ST, Park SH, An JY, Choi MG, Lee JH, Sohn TS, Bae JM. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget. 2017;8:13320-13328. [PMID: 28076847 DOI: 10.18632/oncotarget.14519] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
173 Kakeji Y, Oshikiri T, Takiguchi G, Kanaji S, Matsuda T, Nakamura T, Suzuki S. Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy. Esophagus. 2021;18:25-32. [PMID: 32964312 DOI: 10.1007/s10388-020-00782-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
174 McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M, Gribben JG. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model. Blood 2015;126:212-21. [PMID: 25979947 DOI: 10.1182/blood-2015-02-626754] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 10.4] [Reference Citation Analysis]
175 Enomoto K, Sho M, Wakatsuki K, Takayama T, Matsumoto S, Nakamura S, Akahori T, Tanaka T, Migita K, Ito M, Nakajima Y. Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma. Clin Exp Immunol 2012;168:186-91. [PMID: 22471279 DOI: 10.1111/j.1365-2249.2012.04565.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
176 Däster S, Eppenberger-Castori S, Mele V, Schäfer HM, Schmid L, Weixler B, Soysal SD, Droeser RA, Spagnoli GC, Kettelhack C, Oertli D, Terracciano L, Tornillo L, von Holzen U. Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis. Front Med (Lausanne) 2020;7:144. [PMID: 32411711 DOI: 10.3389/fmed.2020.00144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016;21:462-73. [PMID: 26899259 DOI: 10.1007/s10147-016-0959-z] [Cited by in Crossref: 154] [Cited by in F6Publishing: 149] [Article Influence: 25.7] [Reference Citation Analysis]
178 Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, Rotem-Yehudar R, Kufe D, Avigan D. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011;34:409-18. [PMID: 21577144 DOI: 10.1097/CJI.0b013e31821ca6ce] [Cited by in Crossref: 209] [Cited by in F6Publishing: 134] [Article Influence: 19.0] [Reference Citation Analysis]
179 Laha D, Nilubol N, Boufraqech M. New Therapies for Advanced Thyroid Cancer. Front Endocrinol (Lausanne) 2020;11:82. [PMID: 32528402 DOI: 10.3389/fendo.2020.00082] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
180 Bashir B, Wilson MA. Novel Immunotherapy Combinations. Curr Oncol Rep 2019;21:96. [PMID: 31696332 DOI: 10.1007/s11912-019-0851-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
181 He J, Yi M, Tan L, Huang J, Huang L. The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer. World J Surg Oncol 2021;19:215. [PMID: 34271938 DOI: 10.1186/s12957-021-02325-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 2014;74:4042-52. [PMID: 24812273 DOI: 10.1158/0008-5472.CAN-13-2685] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 10.0] [Reference Citation Analysis]
183 Jesinghaus M, Steiger K, Slotta-Huspenina J, Drecoll E, Pfarr N, Meyer P, Konukiewitz B, Bettstetter M, Wieczorek K, Ott K, Feith M, Langer R, Weichert W, Specht K, Boxberg M. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. Oncotarget 2017;8:46756-68. [PMID: 28657901 DOI: 10.18632/oncotarget.18606] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
184 Wei G, Guo F, Qu A, Jiang W, Jiang Y, Wang J, Jiang P. PD-1 Inhibitor Maintenance Therapy Combined Iodine-125 Seed Implantation Successfully Salvage Recurrent Cervical Cancer after CCRT: A Case Report. Curr Oncol 2021;28:4577-86. [PMID: 34898560 DOI: 10.3390/curroncol28060387] [Reference Citation Analysis]
185 Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis. 2017;8:e3004. [PMID: 28837143 DOI: 10.1038/cddis.2017.401] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
186 Jindal V. Immune checkpoint inhibitors in gastrointestinal malignancies. J Gastrointest Oncol 2018;9:390-403. [PMID: 29755779 DOI: 10.21037/jgo.2018.01.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
187 Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, Schatton T, Asari R, Preusser M, Gnant M, Guenova E, Schoppmann SF. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncoimmunology 2018;7:e1435226. [PMID: 29872575 DOI: 10.1080/2162402X.2018.1435226] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
188 Griffiths JI, Wallet P, Pflieger LT, Stenehjem D, Liu X, Cosgrove PA, Leggett NA, McQuerry JA, Shrestha G, Rossetti M, Sunga G, Moos PJ, Adler FR, Chang JT, Sharma S, Bild AH. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc Natl Acad Sci U S A 2020;117:16072-82. [PMID: 32571915 DOI: 10.1073/pnas.1918937117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
189 Dinesh RK, Hahn BH, Singh RP. PD-1, gender, and autoimmunity. Autoimmun Rev 2010;9:583-7. [PMID: 20433954 DOI: 10.1016/j.autrev.2010.04.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
190 Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F, Perera T, Gammaitoni L, Aglietta M, Comoglio PM, Vigna E, Sangiolo D. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. Br J Cancer 2019;120:527-36. [PMID: 30723303 DOI: 10.1038/s41416-018-0315-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
191 Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006;90:297-339. [PMID: 16730267 DOI: 10.1016/S0065-2776(06)90008-X] [Cited by in Crossref: 356] [Cited by in F6Publishing: 193] [Article Influence: 27.4] [Reference Citation Analysis]
192 Chen CL, Pan QZ, Zhao JJ, Wang Y, Li YQ, Wang QJ, Pan K, Weng DS, Jiang SS, Tang Y, Zhang XF, Zhang HX, Zhou ZQ, Zeng YX, Xia JC. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology. 2016;5:e1176653. [PMID: 27622026 DOI: 10.1080/2162402x.2016.1176653] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
193 Chen CL, Wang Y, Huang CY, Zhou ZQ, Zhao JJ, Zhang XF, Pan QZ, Wu JX, Weng DS, Tang Y, Zhu Q, Yuan LP, Xia JC. IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma. Oncoimmunology 2017;7:e1373234. [PMID: 29296528 DOI: 10.1080/2162402X.2017.1373234] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
194 Martinez-Morilla S, Zugazagoitia J, Wong PF, Kluger HM, Rimm DL. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. Oncoimmunology 2020;10:1864909. [PMID: 33457084 DOI: 10.1080/2162402X.2020.1864909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Wang ZL, Li GZ, Wang QW, Bao ZS, Wang Z, Zhang CB, Jiang T. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. Oncoimmunology 2019;8:e1541535. [PMID: 30713802 DOI: 10.1080/2162402X.2018.1541535] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
196 Groeger S, Howaldt HP, Raifer H, Gattenloehner S, Chakraborty T, Meyle J. Oral Squamous Carcinoma Cells Express B7-H1 and B7-DC Receptors in Vivo. Pathol Oncol Res 2017;23:99-110. [PMID: 27498988 DOI: 10.1007/s12253-016-0100-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
197 Vital D, Ikenberg K, Moch H, Rössle M, Huber GF. The expression of PD-L1 in salivary gland carcinomas. Sci Rep 2019;9:12724. [PMID: 31484986 DOI: 10.1038/s41598-019-49215-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
198 Zhuan-Sun Y, Huang F, Feng M, Zhao X, Chen W, Zhu Z, Zhang S. Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis. Onco Targets Ther 2017;10:5005-12. [PMID: 29081663 DOI: 10.2147/OTT.S146383] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
199 Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S, Amant F. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother 2014;63:545-57. [PMID: 24658839 DOI: 10.1007/s00262-014-1537-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 9.1] [Reference Citation Analysis]
200 Yasuda S, Sho M, Yamato I, Yoshiji H, Wakatsuki K, Nishiwada S, Yagita H, Nakajima Y. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 2013;172:500-6. [PMID: 23600839 DOI: 10.1111/cei.12069] [Cited by in Crossref: 125] [Cited by in F6Publishing: 128] [Article Influence: 13.9] [Reference Citation Analysis]
201 Honda Y, Otsuka A, Ono S, Yamamoto Y, Seidel JA, Morita S, Hirata M, Kataoka TR, Takenouchi T, Fujii K, Kanekura T, Okubo Y, Takahashi K, Yanagi T, Hoshina D, Hata H, Abe R, Fujimura T, Funakoshi T, Yoshino K, Masuzawa M, Amoh Y, Tanaka R, Fujisawa Y, Honda T, Kabashima K. Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. Oncoimmunology 2017;6:e1253657. [PMID: 28197370 DOI: 10.1080/2162402X.2016.1253657] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
202 Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, Shen KH, Chen MK, Lee H, Yeh KT, Chen CJ. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS One 2015;10:e0142656. [PMID: 26562534 DOI: 10.1371/journal.pone.0142656] [Cited by in Crossref: 114] [Cited by in F6Publishing: 114] [Article Influence: 16.3] [Reference Citation Analysis]
203 Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther 2018;3:26. [PMID: 30275987 DOI: 10.1038/s41392-018-0022-9] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 21.8] [Reference Citation Analysis]
204 Kim ST, Ha SY, Lee S, Ahn S, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim KM, Park YS. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. J Cancer. 2016;7:484-489. [PMID: 26958083 DOI: 10.7150/jca.13711] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 10.8] [Reference Citation Analysis]
205 Iijima M, Okonogi N, Nakajima NI, Morokoshi Y, Kanda H, Yamada T, Kobayashi Y, Banno K, Wakatsuki M, Yamada S, Kamada T, Aoki D, Hasegawa S. Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma. J Gynecol Oncol 2020;31:e19. [PMID: 31912675 DOI: 10.3802/jgo.2020.31.e19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
206 Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis 2015;6:e1792. [PMID: 26086965 DOI: 10.1038/cddis.2015.162] [Cited by in Crossref: 360] [Cited by in F6Publishing: 345] [Article Influence: 51.4] [Reference Citation Analysis]
207 Xie QK, Zhao YJ, Pan T, Lyu N, Mu LW, Li SL, Shi MD, Zhang ZF, Zhou PH, Zhao M. Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. Oncoimmunology 2016;5:e1181252. [PMID: 27622038 DOI: 10.1080/2162402X.2016.1181252] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
208 Freeman-Keller M, Weber JS. Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther Adv Med Oncol 2015;7:12-21. [PMID: 25553080 DOI: 10.1177/1758834014551747] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
209 Tang Y, Li G, Wu S, Tang L, Zhang N, Liu J, Zhang S, Yao L. Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers. Oncol Lett 2018;15:4988-96. [PMID: 29552135 DOI: 10.3892/ol.2018.7984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
210 Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, Liu K, Guo W. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol 2018;11:16. [PMID: 29409495 DOI: 10.1186/s13045-018-0560-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 11.3] [Reference Citation Analysis]
211 Ren T, Zheng B, Huang Y, Wang S, Bao X, Liu K, Guo W. Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways. Cell Death Dis 2019;10:261. [PMID: 30886151 DOI: 10.1038/s41419-019-1497-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
212 Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer. 2016;16:434. [PMID: 27393385 DOI: 10.1186/s12885-016-2451-6] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 13.0] [Reference Citation Analysis]
213 Qu HX, Zhao LP, Zhan SH, Geng CX, Xu L, Xin YN, Jiang XJ. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis. J Thorac Dis 2016;8:3197-204. [PMID: 28066599 DOI: 10.21037/jtd.2016.11.01] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
214 Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy. Blood 2013;121:734-44. [PMID: 23223433 DOI: 10.1182/blood-2012-10-385591] [Cited by in Crossref: 103] [Cited by in F6Publishing: 105] [Article Influence: 10.3] [Reference Citation Analysis]
215 Park BV, Freeman ZT, Ghasemzadeh A, Chattergoon MA, Rutebemberwa A, Steigner J, Winter ME, Huynh TV, Sebald SM, Lee SJ, Pan F, Pardoll DM, Cox AL. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discov 2016;6:1366-81. [PMID: 27683557 DOI: 10.1158/2159-8290.CD-15-1347] [Cited by in Crossref: 103] [Cited by in F6Publishing: 66] [Article Influence: 17.2] [Reference Citation Analysis]
216 Yamazoe M, Tomioka H, Kamada T, Kaneko M, Katsuyama E. Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report. Respir Med Case Rep 2019;26:45-9. [PMID: 30533375 DOI: 10.1016/j.rmcr.2018.11.011] [Reference Citation Analysis]
217 Kiaie SH, Sanaei MJ, Heshmati M, Asadzadeh Z, Azimi I, Hadidi S, Jafari R, Baradaran B. Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharm Sin B 2021;11:1083-97. [PMID: 34094821 DOI: 10.1016/j.apsb.2020.12.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
218 Inaguma S, Lasota J, Wang Z, Felisiak-Golabek A, Ikeda H, Miettinen M. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol 2017;30:278-85. [PMID: 27813511 DOI: 10.1038/modpathol.2016.185] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
219 Xing X, Guo J, Ding G, Li B, Dong B, Feng Q, Li S, Zhang J, Ying X, Cheng X, Guo T, Du H, Hu Y, Zhou T, Wang X, Li L, Li Q, Xie M, Li L, Gao X, Shan F, Li Z, Jia S, Wen X, Wang J, Ji J. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology 2018;7:e1356144. [PMID: 29399387 DOI: 10.1080/2162402X.2017.1356144] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 12.6] [Reference Citation Analysis]
220 Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Medicine (Baltimore) 2017;96:e6369. [PMID: 28471952 DOI: 10.1097/MD.0000000000006369] [Cited by in Crossref: 99] [Cited by in F6Publishing: 69] [Article Influence: 19.8] [Reference Citation Analysis]
221 Tan S, Chen D, Liu K, He M, Song H, Shi Y, Liu J, Zhang CW, Qi J, Yan J, Gao S, Gao GF. Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell 2016;7:866-77. [PMID: 27815822 DOI: 10.1007/s13238-016-0337-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
222 Shamsdin SA, Karimi MH, Hosseini SV, Geramizadeh B, Fattahi MR, Mehrabani D, Moravej A. Associations of ICOS and PD.1 Gene Variants with Colon Cancer Risk in The Iranian Population. Asian Pac J Cancer Prev 2018;19:693-8. [PMID: 29580042 DOI: 10.22034/APJCP.2018.19.3.693] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
223 Zuo S, Sho M, Sawai T, Kanehiro H, Maeda K, Yoshida M, Tsukada R, Nomura M, Okuyama H. Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma. Pediatr Surg Int 2020;36:137-43. [PMID: 31925505 DOI: 10.1007/s00383-019-04616-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
224 Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y, Chang XJ, Lu YY, Bai WL, Qu JH, Wang CP, Wang H, Lou M, Wang FS, Lv JY, Yang YP. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One. 2011;6:e23621. [PMID: 21912640 DOI: 10.1371/journal.pone.0023621] [Cited by in Crossref: 100] [Cited by in F6Publishing: 106] [Article Influence: 9.1] [Reference Citation Analysis]
225 Xie G, Li W, Li R, Wu K, Zhao E, Zhang Y, Zhang P, Shi L, Wang D, Yin Y, Deng R, Tao K. Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells. PLoS One 2017;12:e0168822. [PMID: 28056089 DOI: 10.1371/journal.pone.0168822] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
226 Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6:5449-5464. [PMID: 25669979 DOI: 10.18632/oncotarget.3216] [Cited by in Crossref: 261] [Cited by in F6Publishing: 261] [Article Influence: 43.5] [Reference Citation Analysis]
227 Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res 2015;21:4607-18. [PMID: 25979485 DOI: 10.1158/1078-0432.CCR-15-0200] [Cited by in Crossref: 179] [Cited by in F6Publishing: 120] [Article Influence: 25.6] [Reference Citation Analysis]
228 Yang M, Liu P, Wang K, Glorieux C, Hu Y, Wen S, Jiang W, Huang P. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. Mol Oncol 2017;11:358-72. [PMID: 28218497 DOI: 10.1002/1878-0261.12032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
229 Cui P, Jing P, Liu X, Xu W. Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma. Cancer Manag Res 2020;12:5893-902. [PMID: 32765090 DOI: 10.2147/CMAR.S257299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
230 Troiano G, Caponio VCA, Zhurakivska K, Arena C, Pannone G, Mascitti M, Santarelli A, Lo Muzio L. High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature. Cell Prolif 2019;52:e12537. [PMID: 30443950 DOI: 10.1111/cpr.12537] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
231 Cogswell J, Inzunza HD, Wu Q, Feder JN, Mintier G, Novotny J, Cardona DM. An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. Mol Diagn Ther 2017;21:85-93. [PMID: 27667773 DOI: 10.1007/s40291-016-0237-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
232 Ma K, Wei X, Dong D, Wu Y, Geng Q, Li E. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett. 2017;14:250-256. [PMID: 28693161 DOI: 10.3892/ol.2017.6105] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
233 Hatogai K, Kitano S, Fujii S, Kojima T, Daiko H, Nomura S, Yoshino T, Ohtsu A, Takiguchi Y, Doi T, Ochiai A. Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. Oncotarget 2016;7:47252-64. [PMID: 27322149 DOI: 10.18632/oncotarget.10055] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 13.8] [Reference Citation Analysis]
234 Takimoto R, Kamigaki T, Gotoda T, Takahashi T, Okada S, Ibe H, Oguma E, Goto S. Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports. J Med Case Rep 2021;15:191. [PMID: 33827668 DOI: 10.1186/s13256-020-02634-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Jiang L, Wang L, Li PF, Zhang XK, Chen JW, Qiu HJ, Wu XD, Zhang B. Positive Expression of Programmed Death ligand-1 Correlates With Superior Outcomes and Might Be a Therapeutic Target in Primary Pulmonary Lymphoepithelioma-Like Carcinoma. Onco Targets Ther. 2015;8:1451-1457. [PMID: 26109869 DOI: 10.2147/ott.s84234] [Cited by in Crossref: 8] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
236 Śledzińska A, Menger L, Bergerhoff K, Peggs KS, Quezada SA. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol 2015;9:1936-65. [PMID: 26578451 DOI: 10.1016/j.molonc.2015.10.008] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
237 Mkrtichyan M, Chong N, Abu Eid R, Wallecha A, Singh R, Rothman J, Khleif SN. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J Immunother Cancer 2013;1:15. [PMID: 24829751 DOI: 10.1186/2051-1426-1-15] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
238 Zhu X, Zhang Q, Wang D, Liu C, Han B, Yang JM. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Cancer Biol Ther 2019;20:1105-12. [PMID: 30929569 DOI: 10.1080/15384047.2019.1595282] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
239 Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37. [PMID: 22461641 DOI: 10.1126/scitranslmed.3003689] [Cited by in Crossref: 1318] [Cited by in F6Publishing: 1341] [Article Influence: 131.8] [Reference Citation Analysis]
240 Li Y, Huang Q, Zhou Y, He M, Chen J, Gao Y, Wang X. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis. Front Pharmacol 2018;9:1494. [PMID: 30733677 DOI: 10.3389/fphar.2018.01494] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
241 Messerschmidt JL, Prendergast GC, Messerschmidt GL. How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. Oncologist 2016;21:233-43. [PMID: 26834161 DOI: 10.1634/theoncologist.2015-0282] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
242 Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis 2015;36:1085-93. [PMID: 26354776 DOI: 10.1093/carcin/bgv123] [Cited by in Crossref: 148] [Cited by in F6Publishing: 143] [Article Influence: 21.1] [Reference Citation Analysis]
243 Batista S, Gregório AC, Hanada Otake A, Couto N, Costa-Silva B. The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective. J Oncol 2019;2019:6240505. [PMID: 31885581 DOI: 10.1155/2019/6240505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
244 Lohmueller J, Finn OJ. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther. 2017;178:31-47. [PMID: 28322974 DOI: 10.1016/j.pharmthera.2017.03.008] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
245 Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B, Liu X, An G, Zhang W, Zhang J, Zhang L, Zhang S, Yang Y. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Cancer Sci 2016;107:1563-71. [PMID: 27581532 DOI: 10.1111/cas.13072] [Cited by in Crossref: 85] [Cited by in F6Publishing: 94] [Article Influence: 17.0] [Reference Citation Analysis]
246 Ward FJ, Dahal LN, Abu-Eid R. On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. Front Immunol 2018;9:2182. [PMID: 30319637 DOI: 10.3389/fimmu.2018.02182] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
247 Hsieh CC, Hsu HS, Li AF, Chen YJ. Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. J Thorac Dis 2018;10:4433-44. [PMID: 30174892 DOI: 10.21037/jtd.2018.06.167] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
248 Salmaninejad A, Khoramshahi V, Azani A, Soltaninejad E, Aslani S, Zamani MR, Zal M, Nesaei A, Hosseini SM. PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics. 2018;70:73-86. [PMID: 28642997 DOI: 10.1007/s00251-017-1015-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
249 Parikh F, Duluc D, Imai N, Clark A, Misiukiewicz K, Bonomi M, Gupta V, Patsias A, Parides M, Demicco EG, Zhang DY, Kim-Schulze S, Kao J, Gnjatic S, Oh S, Posner MR, Sikora AG. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. Cancer Res. 2014;74:7205-7216. [PMID: 25320012 DOI: 10.1158/0008-5472.can-14-1913] [Cited by in Crossref: 65] [Cited by in F6Publishing: 38] [Article Influence: 8.1] [Reference Citation Analysis]
250 Palicelli A, Bonacini M, Croci S, Magi-Galluzzi C, Cañete-Portillo S, Chaux A, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Zanelli M, Bonasoni MP, De Marco L, Soriano A, Ascani S, Zizzo M, Castro Ruiz C, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Berney DM, Gandhi J, Santandrea G, Gelli MC, Tafuni A, Ragazzi M. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations. Cells 2021;10:3165. [PMID: 34831388 DOI: 10.3390/cells10113165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
251 Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T, Wang Q, Jiang J. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget 2017;8:64066-82. [PMID: 28969052 DOI: 10.18632/oncotarget.19318] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
252 Valentini AM, Di Pinto F, Cariola F, Guerra V, Giannelli G, Caruso ML, Pirrelli M. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget 2018;9:8584-96. [PMID: 29492219 DOI: 10.18632/oncotarget.24196] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
253 Tel J, Hato SV, Torensma R, Buschow SI, Figdor CG, Lesterhuis WJ, de Vries IJ. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunol Immunother 2012;61:1101-11. [PMID: 22193989 DOI: 10.1007/s00262-011-1189-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
254 Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A, Wu X, Cheng X, Xing X, Du H, Wang X, Hu Y, Ji J. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res 2014;26:104-11. [PMID: 24653632 DOI: 10.3978/j.issn.1000-9604.2014.02.08] [Cited by in F6Publishing: 59] [Reference Citation Analysis]
255 Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561-584. [PMID: 26228759 DOI: 10.1038/nrd4591] [Cited by in Crossref: 715] [Cited by in F6Publishing: 687] [Article Influence: 102.1] [Reference Citation Analysis]
256 Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang H, Zhang X, Jiang JT, Wu CP. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med 2015;13:5. [PMID: 25592115 DOI: 10.1186/s12967-014-0373-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
257 Zayac A, Almhanna K. Esophageal, gastric cancer and immunotherapy: small steps in the right direction? Transl Gastroenterol Hepatol 2020;5:9. [PMID: 32190777 DOI: 10.21037/tgh.2019.09.05] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
258 Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, Sicinska E, Goldberg MS, Freeman GJ, Rodig SJ. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunol Res. 2015;3:1123-1129. [PMID: 26081225 DOI: 10.1158/2326-6066.cir-15-0046] [Cited by in Crossref: 81] [Cited by in F6Publishing: 53] [Article Influence: 11.6] [Reference Citation Analysis]
259 Töpfer K, Kempe S, Müller N, Schmitz M, Bachmann M, Cartellieri M, Schackert G, Temme A. Tumor evasion from T cell surveillance. J Biomed Biotechnol 2011;2011:918471. [PMID: 22190859 DOI: 10.1155/2011/918471] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 7.8] [Reference Citation Analysis]
260 Zappasodi R, Wolchok JD, Merghoub T. Strategies for Predicting Response to Checkpoint Inhibitors. Curr Hematol Malig Rep 2018;13:383-95. [PMID: 30159703 DOI: 10.1007/s11899-018-0471-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
261 Wang W, Li F, Mao Y, Zhou H, Sun J, Li R, Liu C, Chen W, Hua D, Zhang X. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet. 2013;132:641-648. [PMID: 23430453 DOI: 10.1007/s00439-013-1275-6] [Cited by in Crossref: 90] [Cited by in F6Publishing: 96] [Article Influence: 10.0] [Reference Citation Analysis]
262 Bertucci F, Finetti P, Perrot D, Leroux A, Collin F, Le Cesne A, Coindre JM, Blay JY, Birnbaum D, Mamessier E. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology 2017;6:e1278100. [PMID: 28405501 DOI: 10.1080/2162402X.2016.1278100] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 8.6] [Reference Citation Analysis]
263 Pectasides E. Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time? J Thorac Dis 2018;10:1276-9. [PMID: 29707278 DOI: 10.21037/jtd.2018.02.74] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
264 Wang Q, Feng F, Wang F, Liu Z, Liu S, Xu G, Zheng G, Guo M, Lian X, Zhang H. PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma. J Cancer 2018;9:2224-31. [PMID: 29937943 DOI: 10.7150/jca.24493] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
265 Zhao JJ, Zhou ZQ, Wang P, Chen CL, Liu Y, Pan QZ, Zhu Q, Tang Y, Weng DS, Xia JC. Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. Cancer Manag Res 2018;10:6457-68. [PMID: 30568505 DOI: 10.2147/CMAR.S181949] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
266 Zhang Y, Zhu W, Zhang X, Qu Q, Zhang L. Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer. Oncol Lett 2017;14:7225-31. [PMID: 29344157 DOI: 10.3892/ol.2017.7105] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
267 Rosenberg AJ, Wainwright DA, Rademaker A, Galvez C, Genet M, Zhai L, Lauing KL, Mulcahy MF, Hayes JP, Odell DD, Horbinski C, Komanduri S, Tetreault MP, Kim KA, Villaflor VM. Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. Oncotarget 2018;9:23482-93. [PMID: 29805749 DOI: 10.18632/oncotarget.25235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
268 Hato SV, de Vries IJ, Lesterhuis WJ. STATing the importance of immune modulation by platinum chemotherapeutics. Oncoimmunology 2012;1:234-6. [PMID: 22720254 DOI: 10.4161/onci.1.2.18126] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 25.0] [Reference Citation Analysis]
269 Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 2016;44:955-72. [PMID: 27192563 DOI: 10.1016/j.immuni.2016.05.002] [Cited by in Crossref: 266] [Cited by in F6Publishing: 256] [Article Influence: 53.2] [Reference Citation Analysis]
270 Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight 2018;3:97941. [PMID: 30385715 DOI: 10.1172/jci.insight.97941] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
271 Kumar AR, Devan AR, Nair B, Vinod BS, Nath LR. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. Mol Biol Rep 2021;48:8075-95. [PMID: 34671902 DOI: 10.1007/s11033-021-06752-9] [Reference Citation Analysis]
272 Han L, Liu F, Li R, Li Z, Chen X, Zhou Z, Zhang X, Hu T, Zhang Y, Young K, Sun S, Wen J, Zhang M. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. Oncol Lett 2014;8:1461-9. [PMID: 25202350 DOI: 10.3892/ol.2014.2356] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
273 Yu W, Guo Y. Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer: A meta-analysis of the literature. Medicine (Baltimore) 2018;97:e11614. [PMID: 30045299 DOI: 10.1097/MD.0000000000011614] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
274 Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H, Esandrio J, Anders RA, Cope L, Pardoll DM, Drake CG, Taube JM. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A 2016;113:E7769-77. [PMID: 27837027 DOI: 10.1073/pnas.1607836113] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 17.5] [Reference Citation Analysis]
275 Huang B, Chen L, Bao C, Sun C, Li J, Wang L, Zhang X. The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis. Onco Targets Ther. 2015;8:2617-2625. [PMID: 26451118 DOI: 10.2147/ott.s91025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
276 Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012;2012:656340. [PMID: 22611421 DOI: 10.1155/2012/656340] [Cited by in Crossref: 193] [Cited by in F6Publishing: 190] [Article Influence: 19.3] [Reference Citation Analysis]
277 Dai C, Geng R, Wang C, Wong A, Qing M, Hu J, Sun Y, Lo AW, Li J. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol Oncol. 2016;10:1551-1558. [PMID: 27720576 DOI: 10.1016/j.molonc.2016.09.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
278 Faluyi OO, Eng L, Qiu X, Che J, Zhang Q, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, Azad AK, Liu G. Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival. Cancer Med. 2017;6:361-373. [PMID: 28074552 DOI: 10.1002/cam4.989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
279 Nicholas S, Mathios D, Ruzevick J, Jackson C, Yang I, Lim M. Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors. Brain Tumor Res Treat 2013;1:2-8. [PMID: 24904882 DOI: 10.14791/btrt.2013.1.1.2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
280 Harada K, Ferdous T, Ueyama Y. PD-L1 expression in malignant salivary gland tumors. BMC Cancer 2018;18:156. [PMID: 29409471 DOI: 10.1186/s12885-018-4069-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
281 Fay AP, Signoretti S, Callea M, Telό GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer 2015;3:3. [PMID: 25767716 DOI: 10.1186/s40425-015-0047-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 7.4] [Reference Citation Analysis]
282 Nassef Kadry Naguib Roufaiel M, Wells JW, Steptoe RJ. Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse? Front Immunol 2015;6:258. [PMID: 26082776 DOI: 10.3389/fimmu.2015.00258] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
283 Li S, Luk HY, Xia C, Chen Z, Chan PKS, Boon SS. Oesophageal carcinoma: The prevalence of DNA tumour viruses and therapy. Tumour Virus Res 2021;13:200231. [PMID: 34920177 DOI: 10.1016/j.tvr.2021.200231] [Reference Citation Analysis]
284 Wei M, Shen D, Mulmi Shrestha S, Liu J, Zhang J, Yin Y. The Progress of T Cell Immunity Related to Prognosis in Gastric Cancer. Biomed Res Int 2018;2018:3201940. [PMID: 29682534 DOI: 10.1155/2018/3201940] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
285 Rong L, Liu Y, Hui Z, Zhao Z, Zhang Y, Wang B, Yuan Y, Li W, Guo L, Ying J, Song Y, Wang L, Zhou Z, Xue L, Lu N. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population. Diagn Pathol 2019;14:6. [PMID: 30684971 DOI: 10.1186/s13000-019-0778-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
286 Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011;17:1915-1923. [PMID: 21355078 DOI: 10.1158/1078-0432.ccr-10-0250] [Cited by in Crossref: 201] [Cited by in F6Publishing: 123] [Article Influence: 18.3] [Reference Citation Analysis]
287 Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, Konishi N, Hirao Y, Nonomura K, Nakajima Y. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer 2011;105:1191-6. [PMID: 21934683 DOI: 10.1038/bjc.2011.368] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
288 Feng Y, Jing C, Yu X, Cao X, Xu C. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1. Hematol Oncol 2020;38:467-77. [PMID: 32515093 DOI: 10.1002/hon.2758] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
289 Han SJ, Ahn BJ, Waldron JS, Yang I, Fang S, Crane CA, Pieper RO, Parsa AT. Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. Neuroreport 2009;20:1597-602. [PMID: 19875977 DOI: 10.1097/WNR.0b013e32833188f7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
290 Chang H, Kim JS, Choi YJ, Cho JG, Woo JS, Kim A, Kim JS, Kang EJ. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Onco Targets Ther 2017;10:2983-92. [PMID: 28652780 DOI: 10.2147/OTT.S134589] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
291 Duan J, Xie Y, Qu L, Wang L, Zhou S, Wang Y, Fan Z, Yang S, Jiao S. A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy. J Immunother Cancer 2018;6:100. [PMID: 30285868 DOI: 10.1186/s40425-018-0418-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
292 Chang CH, Shih AC, Chang YH, Chen HY, Chao YT, Hsu YC. The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis. Front Oncol 2021;11:759497. [PMID: 34868974 DOI: 10.3389/fonc.2021.759497] [Reference Citation Analysis]
293 Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, Kleeff J, Friess H. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009;9:463. [PMID: 20035626 DOI: 10.1186/1471-2407-9-463] [Cited by in Crossref: 92] [Cited by in F6Publishing: 95] [Article Influence: 7.1] [Reference Citation Analysis]
294 Liu J, Liu Y, Wang W, Wang C, Che Y. Expression of immune checkpoint molecules in endometrial carcinoma. Exp Ther Med 2015;10:1947-52. [PMID: 26640578 DOI: 10.3892/etm.2015.2714] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
295 Wang W, Li F, Mao Y, Zhou H, Sun J, Li R, Liu C, Chen W, Hua D, Zhang X. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet. 2013;132:641-648. [PMID: 23430453 DOI: 10.1007/s00439-013-1275.6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
296 Wei B, Wang L, Zhao X, Du C, Guo Y, Sun Z. The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression. Tumour Biol 2014;35:2923-9. [PMID: 24375192 DOI: 10.1007/s13277-013-1376-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
297 Khan H, Gucalp R, Shapira I. Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015;2015:847383. [PMID: 26060497 DOI: 10.1155/2015/847383] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
298 Lu B, Chen L, Liu L, Zhu Y, Wu C, Jiang J, Zhang X. T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol Res. 2011;50:269-275. [PMID: 21717068 DOI: 10.1007/s12026-011-8227-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
299 Burmeister K, Quagliata L, Andreozzi M, Eppenberger-Castori S, Matter MS, Perrina V, Grobholz R, Jochum W, Horber D, Moosmann P, Lehmann F, Köberle D, Ng CK, Piscuoglio S, Tornillo L, Terracciano LM. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PLoS One 2017;12:e0175563. [PMID: 28403223 DOI: 10.1371/journal.pone.0175563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
300 Nishimoto M, Ohara K, Kamamoto D, Tamura R, Miwa T, Yoshida K, Sasaki H. Tumor immune microenvironment is associated with the growth of intracranial germinomas. J Neurooncol 2020;146:139-46. [PMID: 31773448 DOI: 10.1007/s11060-019-03355-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
301 Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696 [PMID: 31011254 DOI: 10.3748/wjg.v25.i14.1684] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
302 Zhang H, Deng M, Lin P, Liu J, Liu C, Strohl WR, Wang S, Ho M. Frontiers and Opportunities: Highlights of the 2nd Annual Conference of the Chinese Antibody Society. Antib Ther 2018;1:65-74. [PMID: 30406214 DOI: 10.1093/abt/tby009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
303 Clay BS, Sperling AI. T-cell costimulation blockade in immunologic diseases: role of CD28 family members. Expert Rev Clin Immunol 2007;3:383-93. [PMID: 20477681 DOI: 10.1586/1744666X.3.3.383] [Reference Citation Analysis]
304 Schiffmann LM, Plum PS, Fuchs HF, Babic B, Bruns CJ, Schmidt T. Tumor Microenvironment of Esophageal Cancer. Cancers (Basel) 2021;13:4678. [PMID: 34572905 DOI: 10.3390/cancers13184678] [Reference Citation Analysis]
305 Fan Y, Ma K, Wang C, Ning J, Hu Y, Dong D, Dong X, Geng Q, Li E, Wu Y. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther. 2016;9:6075-6082. [PMID: 27785054 DOI: 10.2147/ott.s115054] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
306 Zang B, Chen C, Zhao JQ. PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population. Aging (Albany NY) 2020;12:3771-90. [PMID: 32084010 DOI: 10.18632/aging.102845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
307 Schlößer HA, Drebber U, Kloth M, Thelen M, Rothschild SI, Haase S, Garcia-Marquez M, Wennhold K, Berlth F, Urbanski A, Alakus H, Schauss A, Shimabukuro-Vornhagen A, Theurich S, Warnecke-Ebertz U, Stippel DL, Zippelius A, Büttner R, Hallek M, Hölscher AH, Zander T, Mönig SP, von Bergwelt-Baildon M. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. Oncoimmunology 2016;5:e1100789. [PMID: 27467911 DOI: 10.1080/2162402X.2015.1100789] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
308 Pai SI, Zandberg DP, Strome SE. The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral Oncol 2016;61:152-8. [PMID: 27503244 DOI: 10.1016/j.oraloncology.2016.08.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
309 Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011;41:2977-86. [PMID: 21710477 DOI: 10.1002/eji.201141639] [Cited by in Crossref: 108] [Cited by in F6Publishing: 97] [Article Influence: 9.8] [Reference Citation Analysis]
310 Carosio R, Fontana V, Mastracci L, Ferro P, Grillo F, Banelli B, Canessa PA, Dessanti P, Vigani A, Morabito A, Pfeffer U, Poggi A, Roncella S, Pistillo MP. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis. J Cancer Res Clin Oncol 2021;147:459-68. [PMID: 33216211 DOI: 10.1007/s00432-020-03457-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
311 Seo AN, Kang BW, Kwon OK, Park KB, Lee SS, Chung HY, Yu W, Bae HI, Jeon SW, Kang H, Kim JG. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. Br J Cancer 2017;117:1753-60. [PMID: 29073638 DOI: 10.1038/bjc.2017.369] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
312 Feng Y, Shen J, Gao Y, Liao Y, Cote G, Choy E, Chebib I, Mankin H, Hornicek F, Duan Z. Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Oncotarget 2015;6:11139-49. [PMID: 25871477 DOI: 10.18632/oncotarget.3576] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
313 Jiao R, Luo H, Xu W, Ge H. Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities. Onco Targets Ther 2019;12:6023-32. [PMID: 31551657 DOI: 10.2147/OTT.S214579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
314 Weir GM, Liwski RS, Mansour M. Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers (Basel) 2011;3:3114-42. [PMID: 24212948 DOI: 10.3390/cancers3033114] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
315 Ando K, Hamada K, Shida M, Ohkuma R, Kubota Y, Horiike A, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S. A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:337-48. [PMID: 32757055 DOI: 10.1007/s00262-020-02686-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
316 Zheng Y, Yang Y, Wu S, Zhu Y, Tang X, Liu X. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered 2017;8:367-73. [PMID: 27754760 DOI: 10.1080/21655979.2016.1230573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
317 Tamai K, Nakamura M, Mizuma M, Mochizuki M, Yokoyama M, Endo H, Yamaguchi K, Nakagawa T, Shiina M, Unno M, Muramoto K, Sato I, Satoh K, Sugamura K, Tanaka N. Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma. Cancer Sci. 2014;105:667-674. [PMID: 24673799 DOI: 10.1111/cas.12406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
318 Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H, Nakajima Y. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009;101:1709-16. [PMID: 19844235 DOI: 10.1038/sj.bjc.6605375] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 7.7] [Reference Citation Analysis]
319 Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol 2014;193:3835-41. [PMID: 25281753 DOI: 10.4049/jimmunol.1401572] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 15.4] [Reference Citation Analysis]
320 Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One. 2015;10:e0131403. [PMID: 26114883 DOI: 10.1371/journal.pone.0131403] [Cited by in Crossref: 187] [Cited by in F6Publishing: 206] [Article Influence: 26.7] [Reference Citation Analysis]
321 Hashimoto K, Nishimura S, Ito T, Akagi M. Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas. Eur J Histochem 2021;65. [PMID: 34218652 DOI: 10.4081/ejh.2021.3203] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
322 Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D, van Laere S. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget 2015;6:13506-19. [PMID: 25940795 DOI: 10.18632/oncotarget.3642] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 11.8] [Reference Citation Analysis]
323 Zhang W, Wang P, Pang Q. Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review. Ann Transl Med 2020;8:1193. [PMID: 33241042 DOI: 10.21037/atm-20-4625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
324 Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, Luo H, Yang YX, Dai XY, Zhou SF, Wang D. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 2015;9:901-909. [PMID: 25733810 DOI: 10.2147/dddt.s75152] [Cited by in Crossref: 90] [Cited by in F6Publishing: 70] [Article Influence: 12.9] [Reference Citation Analysis]
325 Chen J, Wu XJ, Wang GQ. Hepatoma cells up-regulate expression of programmed cell death-1 on T cells. World J Gastroenterol 2008; 14(44): 6853-6857 [PMID: 19058313 DOI: 10.3748/wjg.14.6853] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
326 Li Q, Li F, Che J, Zhao Y, Qiao C. Expression of B7 Homolog 1 (B7H1) Is Associated with Clinicopathologic Features in Urothelial Bladder Cancer. Med Sci Monit 2018;24:7303-8. [PMID: 30315148 DOI: 10.12659/MSM.910956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
327 Philips EA, Garcia-España A, Tocheva AS, Ahearn IM, Adam KR, Pan R, Mor A, Kong XP. The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals. J Biol Chem 2020;295:4372-80. [PMID: 31882544 DOI: 10.1074/jbc.AC119.011747] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
328 Lan A, Ren C, Wang X, Tong G, Yang G. Bioinformatics and survival analysis of glia maturation factor-γ in pan-cancers. BMC Cancer 2021;21:423. [PMID: 33863293 DOI: 10.1186/s12885-021-08163-2] [Reference Citation Analysis]